Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by research analysts at BMO Capital Markets to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports.
ALNY has been the topic of several other reports. Wells Fargo & Company decreased their price target on shares of Alnylam Pharmaceuticals from $316.00 to $256.00 and set an “equal weight” rating on the stock in a research report on Friday, August 14th. Bank of America cut their price objective on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating for the company in a research report on Tuesday, July 14th. Sanford C. Bernstein upgraded shares of Alnylam Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, July 29th. Royal Bank Of Canada decreased their target price on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. Finally, Weiss Ratings upgraded Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 31st. Four investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $386.62.
View Our Latest Stock Analysis on ALNY
Alnylam Pharmaceuticals Stock Up 6.1%
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The business had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same quarter in the previous year, the firm posted ($0.51) earnings per share. Alnylam Pharmaceuticals’s revenue was up 66.9% compared to the same quarter last year. On average, equities analysts predict that Alnylam Pharmaceuticals will post 6.59 EPS for the current year.
Insider Transactions at Alnylam Pharmaceuticals
In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the transaction, the director directly owned 1,582 shares in the company, valued at $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by corporate insiders.
Institutional Trading of Alnylam Pharmaceuticals
Hedge funds have recently modified their holdings of the company. MV Capital Management Inc. bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $25,000. HM Payson & Co. bought a new stake in Alnylam Pharmaceuticals during the 4th quarter worth approximately $27,000. Golden State Wealth Management LLC grew its position in Alnylam Pharmaceuticals by 100.0% during the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 36 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at $29,000. Finally, Manchester Capital Management LLC increased its holdings in Alnylam Pharmaceuticals by 600.0% during the 4th quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 72 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.
Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.
Featured Stories
- Five stocks we like better than Alnylam Pharmaceuticals
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
